GlassScriptPhysician profile
Scott D Doll
NPI 1033685847
$6,008.25
in general payments reported to CMS, 2019-2025
42 companies · $2,549 in 2025
The $2,549 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $740 · 2023: $889 · 2024: $1,830 · 2025: $2,549.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,250 · Education: $17.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,250.44 |
| Education | $17.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $606.50 | 2022-2025 | Briviact, Nayzilam, Rystiggo |
| Eisai INC. | $592.61 | 2023-2025 | |
| Lilly USA, LLC | $542.80 | 2022-2025 | Amyvid, Emgality, Kisunla |
| Abbvie INC. | $479.68 | 2023-2025 | |
| Pfizer INC. | $461.10 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $401.86 | 2023-2025 | Hyqvia |
| Harmony Biosciences LLC | $310.50 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $276.57 | 2022-2025 | |
| Livanova USA, INC. | $207.84 | 2024-2025 | Vns Therapy Sentiva Model 1000 Generator, Vns Therapy |
| Grifols USA, LLC | $165.54 | 2022-2025 | Gamunex-C |
| Janssen Biotech, INC. | $157.63 | 2025 | |
| Sk Life Science, INC. | $145.20 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $144.21 | 2022-2025 | Ultomiris |
| Argenx US, INC. | $138.40 | 2024-2025 | Vyvgart Hytrulo |
| Avadel Cns Pharmaceuticals, LLC | $117.19 | 2024-2025 | Lumryz |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $115.87 | 2022-2025 | Austedo Xr |
| Axsome Therapeutics, INC. | $105.64 | 2023-2025 | Sunosi |
| Ge Healthcare | $104.93 | 2023-2025 | |
| Lundbeck LLC | $81.93 | 2024-2025 | Vyepti, Abilify Maintena, Rexulti |
| Fisher & Paykel Healthcare INC | $79.08 | 2022-2025 | Fisher & Paykel Healthcare |
| Amneal Pharmaceuticals LLC | $77.94 | 2022-2025 | Rytary, Crexont |
| Inspire Medical Systems, INC. | $76.58 | 2024-2025 | Inspire |
| Biogen, INC. | $70.92 | 2025 | Leqembi |
| Amgen INC. | $62.06 | 2022 | |
| C2n Diagnostics, LLC | $57.54 | 2025 | Precivityad2 |
| Zoll Respicardia, INC. | $53.36 | 2023-2025 | Remede System |
| Otsuka America Pharmaceutical, INC. | $45.63 | 2023 | Rexulti, Nuedexta |
| Biohaven Pharmaceutical Holding Company LTD. | $35.69 | 2022 | |
| Alnylam Pharmaceuticals INC. | $28.27 | 2022 | |
| Life Molecular Imaging LTD | $26.77 | 2025 | Neuraceq |
| Microtransponder, INC. | $25.81 | 2024 | |
| Xeris Pharmaceuticals, INC. | $23.78 | 2022 | |
| Resmed Corp | $22.38 | 2025 | |
| Csl Behring | $22.06 | 2025 | Hizentra |
| Impel Pharmaceuticals LLC | $21.33 | 2025 | Trudhesa |
| Tanabe Pharma America, INC. | $19.90 | 2025 | Radicava |
| Averitas Pharma INC. | $19.69 | 2025 | Qutenza |
| Genentech USA, INC. | $18.75 | 2024 | Ocrevus |
| Azurity Pharmaceuticals, INC. | $18.75 | 2023 | Horizant |
| Janssen Pharmaceuticals, INC | $17.90 | 2025 | |
| Supernus Pharmaceuticals, INC. | $16.31 | 2025 | Qelbree |
| Arbor Pharmaceuticals, INC. | $11.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Doll listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.